Compare Stocks: HUMA, VALN, SVA, and AUTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.36 +1.3%	$1.80	$1.17 ▼ $2.58	$620.16M	2.07	3.55 million shs	1.23 million shs
HUMA Humacyte	$0.69 +1.6%	$0.69	$0.53 ▼ $2.55	$189.35M	2.53	8.89 million shs	2.91 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A
VALN Valneva	$6.56 -2.1%	$5.51	$4.75 ▼ $12.23	$635.26M	1.77	186,461 shs	21,499 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+1.29%	-4.07%	+62.76%	+26.20%	+50.32%
HUMA Humacyte	+1.63%	+1.66%	+9.83%	-46.72%	-54.73%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
VALN Valneva	-2.09%	-3.81%	+29.64%	+4.96%	-25.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.36 +1.3%	$1.80	$1.17 ▼ $2.58	$620.16M	2.07	3.55 million shs	1.23 million shs
HUMA Humacyte	$0.69 +1.6%	$0.69	$0.53 ▼ $2.55	$189.35M	2.53	8.89 million shs	2.91 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.79	N/A	N/A
VALN Valneva	$6.56 -2.1%	$5.51	$4.75 ▼ $12.23	$635.26M	1.77	186,461 shs	21,499 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+1.29%	-4.07%	+62.76%	+26.20%	+50.32%
HUMA Humacyte	+1.63%	+1.66%	+9.83%	-46.72%	-54.73%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
VALN Valneva	-2.09%	-3.81%	+29.64%	+4.96%	-25.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	323.73% Upside
HUMA Humacyte	2.71	Moderate Buy	$6.54	844.37% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
VALN Valneva	2.00	Hold	$9.30	41.77% Upside

Current Analyst Ratings Breakdown

Latest HUMA, VALN, SVA, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$2.00 ➝ $1.00
8/12/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/3/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/31/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
7/8/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	VALN Valneva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$75.39M	8.33	N/A	N/A	$0.28 per share	8.43
HUMA Humacyte	$2.12M	90.73	N/A	N/A	$0.11 per share	6.30
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$64.88 per share	0.10
VALN Valneva	$197.56M	3.15	N/A	N/A	$0.99 per share	6.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VALN Valneva	-$130.33M	-$2.11	N/A	14.91	N/A	-110.33%	-153.20%	-39.50%	N/A

Latest HUMA, VALN, SVA, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
HUMA Humacyte	2.07	6.21	5.74
SVA Sinovac Biotech	0.04	6.07	5.97
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
HUMA Humacyte	44.71%
SVA Sinovac Biotech	N/A
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
HUMA Humacyte	3.10%
SVA Sinovac Biotech	12.79%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.16 million	197.76 million	Optionable
HUMA Humacyte	150	277.80 million	269.19 million	Optionable
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
VALN Valneva	700	94.89 million	80.74 million	Not Optionable

HUMA, VALN, SVA, and AUTL Headlines

Recent News About These Companies

Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of "Hold" by Analysts

August 25 at 6:13 AM | marketbeat.com

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile

August 24, 2026 | ad-hoc-news.deA

Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why

August 24, 2026 | marketbeat.com

Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight

August 20, 2026 | ad-hoc-news.deA

Valneva (VALN) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

Research Analysts Issue Forecasts for Valneva Q3 Earnings

August 18, 2026 | marketbeat.com

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine

August 17, 2026 | pharmabiz.comP

EMA validates Pfizer and Valneva’s Lyme disease vaccine

August 17, 2026 | msn.com

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15, 2026 | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15, 2026 | marketwatch.com

Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review

August 15, 2026 | finance.yahoo.com

Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS

August 14, 2026 | marketbeat.com

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next?

August 14, 2026 | marketbeat.com

A Lyme disease vaccine may finally be on the way. Why did it take so long?

August 14, 2026 | nationalpost.comN

EU to study potential vaccine for Lyme disease: companies

August 14, 2026 | yahoo.com

Valneva SE 2026 Q2 - Results - Earnings Call Presentation

August 14, 2026 | seekingalpha.com

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

August 14, 2026 | globenewswire.com

Valneva SE (INRLF) (H1 2026) Earnings Call Highlights: Strategic Pivot and Lyme Vaccine ...

August 13, 2026 | finance.yahoo.com

Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 months

August 13, 2026 | seekingalpha.com

Valneva SE (VALN) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Valneva Q2 Earnings Call Highlights

August 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HUMA, VALN, SVA, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.36 +0.03 (+1.29%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$2.38 +0.02 (+0.64%)

As of 07:07 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Humacyte NASDAQ:HUMA

$0.69 +0.01 (+1.63%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$0.71 +0.02 (+2.21%)

As of 07:24 AM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 08/26/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Valneva NASDAQ:VALN

$6.56 -0.14 (-2.09%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$6.76 +0.20 (+3.06%)

As of 07:02 AM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUMA, VALN, SVA, and AUTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUMA, VALN, SVA, and AUTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUMA, VALN, SVA, and AUTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUMA, VALN, SVA, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Humacyte NASDAQ:HUMA

Sinovac Biotech NASDAQ:SVA

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HUMA, VALN, SVA, and AUTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HUMA, VALN, SVA, and AUTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HUMA, VALN, SVA, and AUTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HUMA, VALN, SVA, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Humacyte NASDAQ:HUMA

Sinovac Biotech NASDAQ:SVA

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools